date]Cell Therapeutics Inc • March 16th, 2009 • Pharmaceutical preparations
You (“Executive”) and Cell Therapeutics, Inc., a Washington corporation (“CTI” or the “Company”), previously entered into a Severance Agreement dated ___________ (the “Severance Agreement”). This letter agreement amends the Severance Agreement to the extent necessary to provide that the severance benefits set forth therein comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended. Except as otherwise amended pursuant to this letter agreement, the Severance Agreement remains in full force and effect. Any terms used but not otherwise defined herein shall have the meaning set forth in the Severance Agreement.
FIRST AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • March 16th, 2009 • Cell Therapeutics Inc • Pharmaceutical preparations • California
This First Amendment to Asset Purchase Agreement (this “Amendment”), dated as of December 9, 2008 (the “Effective Date”), is made by and between CELL THERAPEUTICS, INC., a Washington corporation (“Buyer”), and BIOGEN IDEC INC., a Delaware corporation (“Seller”), with reference to the following facts:
TERMINATION AGREEMENTTermination Agreement • March 16th, 2009 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
This Termination Agreement (“Agreement”) is made and entered into as of March 5, 2009 by and between Cell Therapeutics, Inc., a Washington corporation (the “Company”) and Midsummer Investment, Ltd., a Bermuda corporation (“Purchaser”). The Company and Purchaser are each referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDED AND RESTATED SECURITY AGREEMENTAmended and Restated Security Agreement • March 16th, 2009 • Cell Therapeutics Inc • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED SECURITY AGREEMENT (this “Agreement”), dated as of December 15, 2008 (the “Effective Date”), is made by and between CELL THERAPEUTICS, INC., a Washington corporation (“CTI”), and BIOGEN IDEC INC., a Delaware corporation (“BIIB”).
December 31, 2008Cell Therapeutics Inc • March 16th, 2009 • Pharmaceutical preparations
You (“Employee”) and Cell Therapeutics, Inc., a Washington corporation (“CTI” or the “Company”) previously entered into an employment agreement dated April 23, 2008 (the “Employment Agreement”). This letter agreement amends the Employment Agreement to the extent necessary to provide that the termination benefits set forth therein will comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended. Except as otherwise amended pursuant to this letter agreement, the Employment Agreement remains in full force and effect. Any terms used but not otherwise defined herein shall have the meaning set forth in the Employment Agreement.
FORM OF STRATEGIC MANAGEMENT TEAM SEVERANCE AGREEMENTSeverance Agreement • March 16th, 2009 • Cell Therapeutics Inc • Pharmaceutical preparations • Washington
This SEVERANCE AGREEMENT (the “Agreement”) is entered into by and between Cell Therapeutics, Inc., a Washington corporation (“CTI” or the “Company”), and _____________ (the “Executive”).
